He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
Cancer cases in India estimated to reach 1.57 million in 2025
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.
The FDA determined that the data presented in a 2022 color additive petition show that this ingredient causes cancer in male laboratory rats exposed to high levels of FD&C Red No. 3 because of a hormonal mechanism that occurs in male rats
The site’s GMP Certification has been successfully renewed
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
Subscribe To Our Newsletter & Stay Updated
